Baxter Reveals Encouraging Bird Flu Vaccine Data
Posted on: Friday, 30 March 2007, 09:00 CDT
Baxter International has said that final phase I/II data for its investigational pandemic H5N1 influenza vaccine was promising and as a result the company plans to initiate a phase III trial of the candidate vaccine in Europe to confirm the study results.
The phase I/II study indicated that Baxter's H5N1 candidate vaccine is highly immunogenic at low doses, and induces substantial levels of cross immunity against widely divergent H5N1 strains.
The phase III trial is designed to evaluate the safety and efficacy of Baxter's adjuvant-free, whole-virus candidate vaccine. Vaccinations will begin in the first half of this year and results of the phase III trial are scheduled to be available by the end of 2007. Recipients will be evaluated for the vaccine's ability to elicit the production of antibodies to the H5N1 strain A/Vietnam/1203/2004, which is the strain used for the vaccine, and also against a number of other divergent H5N1 strains.
Baxter's candidate H5N1 vaccine is manufactured using the company's proprietary vero cell technology, which produces high-yield vaccine more quickly than traditional approaches because it is not produced in eggs. Baxter's candidate vaccine is the first cell-based candidate H5N1 pandemic vaccine to undergo clinical evaluation.
Source: Datamonitor
Related Articles
- PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryx's Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
- ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week
- BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
- Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
- Metabolex Initiates Phase II/III Trial of Insulin Sensitizer
- Sinovac Completes Immunization Schedule in the Phase I Clinical Trial of Its Proprietary Avian Influenza Vaccine (H5N1)
- IDM Presents Results of Its Phase I Trial of Its Collidem(R) Dendritic Cell Vaccine in Patients With Advanced Colorectal Cancer at GI-ASCO Meeting in San Francisco
- Cell Genesys Reports Positive Results From Phase 2 Trial of GVAX(R) Vaccine for Leukemia in Chronic Myelogenous Leukemia
- Cell Genesys Reports Additional Positive Data From Phase 2 Trial of GVAX(R) Vaccine for Leukemia
- Cell Genesys Reports Encouraging Follow Up Clinical Data From Phase 2 Trial of GVAX(R) Leukemia Vaccine
 |
 |
User Comments (0)
RSS Feeds